FDA Inspection 1326180 — Weiwei Ouyang
The FDA completed an inspection of Weiwei Ouyang on Jun 18, 2026 in Guiyang. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jun 18, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Guiyang (China)
Additional Details
Clinical BA/BE